NewsResearch
FDA Approval: Rucaparib (Rubraca) for Ovarian Cancer
FDA approved Rucaparib (Rubraca), a PARP inhibitor, for certain people with ovarian cancer. What was approved, the evidence, and what it does and doesn't mean.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Breaking the spare repair kit
Cells damage their own DNA constantly, and repair it constantly. They keep more than one repair route for the job.
PARP is a family of enzymes that handles one of those routes. Rucaparib blocks PARP-1, PARP-2 and PARP-3. On its own that is survivable: a healthy cell uses the other route.
BRCA1 and BRCA2 run that other route. A cell whose BRCA gene is broken has already lost it. Block PARP as well and the cell has no way to fix the breaks. Damage piles up and the cell dies. The label adds that rucaparib also traps PARP onto the DNA itself, which makes the damage worse.
This is why the drug is aimed, not general. About 15% to 20% of ovarian cancers carry a BRCA mutation, according to NCI. Our page on targeted therapy covers why a target has to be found before a targeted drug is chosen.
The 2016 approval, and why it is no longer on the label
FDA granted accelerated approval on December 19, 2016. It covered women whose ovarian cancer had progressed after two or more chemotherapies and whose tumors carried a BRCA1 or BRCA2 mutation, found by an approved companion test.
The evidence was two early-phase trials, 106 women in total. More than half had tumors shrink completely or partly, and those responses lasted a median of just over nine months. There was no comparison group.
That indication is gone. The prescribing information as revised in December 2025 no longer lists treatment of previously treated ovarian cancer at all. This is what accelerated approval is designed to allow: a drug reaches patients on early evidence, and the indication stands or falls on what the confirmatory trials show.
What the label covers today
Two uses remain.
For ovarian cancer, rucaparib is maintenance treatment. It is for adults with a BRCA mutation, inherited or acquired by the tumor, whose recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer is in complete or partial response to platinum chemotherapy. Maintenance means it starts after chemotherapy has already worked, to hold the result.
It also treats metastatic castration-resistant prostate cancer with a BRCA mutation, after androgen receptor-directed therapy, selected by a companion test.
The dose is 600 mg by mouth twice a day, with or without food, continued until the disease grows or side effects become unacceptable.
That is the licensed reference amount. Go by the prescription your own team wrote, since they lower it when blood tests or side effects call for that.
ARIEL3, and two different questions
The ovarian indication rests on ARIEL3, a double-blind trial of 564 women already responding to platinum chemotherapy. They were randomly assigned two to one to rucaparib or placebo. Of those, 196 had a tumor BRCA mutation, and that group is where the label's numbers come from.
Median progression-free survival was 16.6 months with rucaparib and 5.4 months with placebo, a hazard ratio of 0.23. That is a large delay in the cancer growing again.
Overall survival is a separate question, and the answer was different. In the final analysis, median overall survival was 45.9 months with rucaparib and 47.8 months with placebo, with a hazard ratio of 0.83 and a confidence interval that crosses 1.
Both facts are true at once. The drug kept disease at bay much longer, and the trial did not show that people lived longer overall. Time without progression can matter on its own, through fewer symptoms and a break from chemotherapy. The label does not claim otherwise. Our page on clinical trial phases explains why these endpoints are reported separately.
The warning that drives monthly blood tests
PARP inhibitors carry a risk of myelodysplastic syndrome and acute myeloid leukemia, two bone marrow cancers. The label reports these in 34 of 2,141 treated patients, or 1.6%, including long-term follow-up. In the ARIEL3 BRCA group they occurred in 9 of 129 on rucaparib and 4 of 66 on placebo, and some cases were fatal.
Every patient in these trials had already had platinum chemotherapy, which itself damages DNA, so the two exposures are hard to separate.
The practical result is monitoring. Blood counts are checked before starting and monthly after. If low counts last more than four weeks, the drug is paused or reduced. If marrow disease is confirmed, it is stopped for good.
Side effects reported in at least 10% of ovarian cancer patients include nausea, fatigue, anemia, raised liver enzymes, vomiting, diarrhea, low appetite, low blood counts, taste changes and sun sensitivity.
When to get checked
Ovarian cancer is hard to catch early because it often causes nothing until it has spread. There is no screening test for women at average risk. NCI lists symptoms that warrant a doctor's visit if they get worse or do not settle:
- Pain, swelling or a feeling of pressure in the abdomen or pelvis.
- A sudden or frequent urge to urinate.
- Trouble eating, or feeling full quickly.
- A lump in the pelvic area.
- Gas, bloating or constipation that persists.
The rule of thumb clinicians use is persistence. Bloating for a day is nothing. Bloating most days for several weeks, in someone for whom that is new, is worth investigating. Our page on ovarian cancer covers the tests that follow.
The wider numbers
About 21,010 new ovarian cancers and about 12,450 deaths are expected in the United States in 2026, on American Cancer Society projections that SEER republishes. Five-year relative survival for 2016 to 2022 was 52.0%, and the median age at diagnosis is 63.
Stage explains the gap. Across the same 2016 to 2022 group, survival is 91.9% when the cancer is still confined to the ovary, 70.1% with regional spread, and 31.5% once it is distant. Only 22% are found at that first stage; 54% are already distant. These are group figures from a whole population and describe no one person.
What this approval cannot tell you
It cannot tell you whether rucaparib fits a particular person. That depends on BRCA status, response to the last platinum course, blood counts, kidney and liver function, and what has been used already.
It cannot promise longer life. ARIEL3 did not show that, and the label reports the result plainly.
And it cannot be read as permanent. One ovarian indication has already been removed from this label. What a drug is approved for in 2026 may not be what it was approved for in 2016, or what it will be in 2030.
Sources
- NCI Cancer Currents, FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer — https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-rucaparib-ovarian
- DailyMed, RUBRACA (rucaparib) tablets prescribing information, revised December 2025 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0295d202-1cfe-7659-e063-6294a90a476e
- NCI PDQ, Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (Patient Version) — https://www.cancer.gov/types/ovarian/patient/ovarian-epithelial-treatment-pdq
- SEER Cancer Stat Facts, Ovarian Cancer — https://seer.cancer.gov/statfacts/html/ovary.html
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Ovarian cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.